Trial · NCT07894601
Virtual Reality Intervention to Improve Comfort in Hospitalized Hematology Patients
NCT07894601, Not applicable, Recruiting, Fundación para la Investigación del Hospital Clínico de Valencia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Virtual Reality Intervention to Improve Comfort in Hospitalized Hematology Patients. Trials, record NCT07894601. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07894601
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Virtual Reality Intervention to Improve Comfort in Hospitalized Hematology Patients
- NCT number
- NCT07894601
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 145 participants, estimated
- Lead sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
- Conditions
- Hematologic Cancer
- Interventions
- Immersive virtual reality experience
- First posted
- 2026-10-26
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To determine the effectiveness of using VR headsets in improving the comfort of hematology patients during their hospital stay with the General Comfort Questionnaire (GCQ). | At day 5 of hospital admission and on day 22 of hospital admission. If the hospital stay is shorter than 22 days, the second assessment will be performed before hospital discharge. | The GCQ consists of 48 items rated on a 4-point Likert scale, ranging from 1 (strongly disagree) to 4 (strongly agree). It includes 24 positively worded items and 24 negatively worded items, with the latter being reverse-scored. The questionnaire assesses comfort across four contexts (physical, psychospiritual, sociocultural, and environmental) and considers three types of comfort: relief, ease, and transcendence. It is designed for self-administration. The total score ranges from 48 to 192, with higher scores indicating greater comfort. |
| Secondary | To assess the quality of life of hospitalized hematology patients with EORTC QLQ-C30. | Atnday 5 of hospital admission and on day 22 of hospital admission. If the hospital stay is shorter than 22 days, the second assessment will be performed before hospital discharge. | EORTC QLQ-C30 is a questionnaire on quality of life in cancer patients (widely used in clinical trials) comprising 5 functional domains (physical, role, emotional, cognitive, and social), 3 symptom domains (nausea and vomiting, pain, and fatigue), a global scale for physical health and quality of life, and, finally, 6 individual items that assess financial difficulties, diarrhea, constipation, loss of appetite, insomnia, and shortness of breath. The questionnaire is scored as follows: (1: not at all, 2: a little, 3: quite a bit, 4: very much), with two additional items rated on a scale from 1 (very poor) to 7 (excellent). |
| Secondary | Analyze immediate well-being when using VR headsets, using a visual analogue scale (VAS) and the "Edmonton Symptom Assessment System" questionnaire. | Before the intervention and immediately after the intervention at days 5, 8,15 and 22 of hospital admission. | The VAS scale allows the patient to express their level of well-being, with 1 representing no well-being and 10 representing the highest level of well-being. Edmonton Symptom Assessment System: A scale that measures physical and psychological symptoms; it is widely used among cancer patients and has been validated in Spanish. It consists of 10 items to be rated, with scores ranging from 0 (no symptom) to 10 (the worst). |
| Secondary | Identify potential adverse effects when using the VR tool with "Simulator Sickness Questionnaire". | Immediately after the intervention at days 5, 8,15 and 22 of hospital admission. | Simulator Sickness Questionnaire: original scale created by Kennedy et al. (1993) to measure the 16 potential effects of virtual reality, grouped into three dimensions (oculomotor, disorientation, and nausea), which has been translated into and validated for Spanish. Scores range from 0 (absent) to 3 (severe). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07894601
GET https://conductscience.org/api/trials/v1/NCT07894601/registered